After a disappointing end to a nine-year trial, the U.S. Food and Drug Administration officially gave AMAG Pharmaceuticals notice of the proposal to withdraw approval of Makena, an injectable progestin treatment to reduce preterm births.  

The U.S. Food and Drug Administration is requesting makers of all versions of the heartburn drug Zantac to remove the products from the market immediately due to the presence of a probable carcinogen.

The U.S. Food and Drug Administration called for Eisai to pull the company’s Belviq and Belviq XR for weight loss from the market after clinical trials demonstrated an increased incidence of cancer in users.